Novartis AG Total Depreciation and Amortization - Cash Flow 2010-2025 | NVS
Novartis AG annual/quarterly total depreciation and amortization - cash flow history and growth rate from 2010 to 2025. Total depreciation and amortization - cash flow can be defined as the total amount of depreciation and amortization listed on the Cash Flows Statement
- Novartis AG total depreciation and amortization - cash flow for the quarter ending March 31, 2025 was $1.195B, a 10.95% decline year-over-year.
- Novartis AG total depreciation and amortization - cash flow for the twelve months ending March 31, 2025 was $11.763B, a 28.64% decline year-over-year.
- Novartis AG annual total depreciation and amortization - cash flow for 2024 was $6.114B, a 27.07% decline from 2023.
- Novartis AG annual total depreciation and amortization - cash flow for 2023 was $8.383B, a 20.36% increase from 2022.
- Novartis AG annual total depreciation and amortization - cash flow for 2022 was $6.965B, a 0% decline from 2021.
Novartis AG Annual Total Depreciation and Amortization - Cash Flow
(Millions of US $) |
| 2024 |
$6,114 |
| 2023 |
$8,383 |
| 2022 |
$6,965 |
| 2021 |
$N/A |
| 2020 |
$6,129 |
| 2019 |
$5,788 |
| 2018 |
$5,217 |
| 2017 |
$6,076 |
| 2016 |
$6,043 |
| 2015 |
$5,471 |
| 2014 |
$N/A |
| 2013 |
$4,462 |
| 2012 |
$N/A |
| 2011 |
$5,980 |
| 2010 |
$3,577 |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$231.500B |
$50.317B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
